Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPrognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin–Frankfurt–Münster (BFM) protocols containing early and late re-intensification elements
British Journal of Haematology, 10/16/09
Attarbaschi A et al. – Although molecular disease was frequently present after a 4–drug induction therapy, final treatment outcome was excellent indicating that TLX3+ T–ALL cases may benefit from a BFM–type of ALL therapy with early and late re–intensification elements. Moreover, the fact that 2/3 relapses were also NUP214–ABL1+ suggests that these cases might represent the particular risk–prone TLX3+ subgroup that could benefit from a targeted tyrosine kinase inhibitor therapy.
Related Articles
Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia
British Journal of Haematology, 10/05/09
Relevance Score: 81%
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
British Journal of Haematology, 11/04/09
Relevance Score: 80%
Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups – a UKALLXII study
British Journal of Haematology, 11/11/09
Relevance Score: 79%
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia
British Journal of Haematology, 10/16/09
Relevance Score: 67%
Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia
International Journal of Hematology, 10/13/09
Relevance Score: 66%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by deltaNp73 in Neuroblastoma
Molecular Cancer Research, 12/04/09
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression
Virchows Archiv, 12/04/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue
Journal of Neuro-Oncology, 12/04/09
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/03/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor